Informa Australia is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Find Topic


Biologic treatments for rheumatoid arthritis to capture greater market share

[tweetmeme source= "informa_oz" only_single=false] Melbourne, 30th September 2010 - Use of biologic disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis is set to increase dramatically over the next five years finds independent market analyst, Datamonitor. Despite their considerable cost, rheumatologists interviewed by Datamonitor in the US, Europe and Japan expect a continued increase…

30 Sep 2010, by Informa Insights


Venture Financing in Asia-Pacific looks promising

[tweetmeme source= "informa_oz" only_single=false] Melbourne – 28th September 2010 – MedTRACK, a market leading database of private and public biomedical companies, reports that the number of transactions in the Asia-Pacific region is on pace to rebound by 15% in 2010. Sarah Terry, President of MedTRACK comments: To be a company in Asia-Pacific region is really…

28 Sep 2010, by Informa Insights


Antidyslipidemics | End of an Era

[tweetmeme source= "informa_oz" only_single=false] The domination of the antidyslipidemic market by five top brands is set to fundamentally change over the next 10 years as novel agents fail to meet the success of their predecessors, claims a new report from independent market analyst, Datamonitor. The top five antidyslipidemic brands: Lipitor (atorvastatin, Pfizer), Crestor (rosuvastatin, AstraZeneca),…

28 Sep 2010, by Informa Insights


Cancer Targeted Therapies and Immunotherapies | Resisting Competitive Pressures

[tweetmeme source= "informa_oz" only_single=false] Drug developers aiming to emulate the success of cancer targeted therapies and immunotherapy brands will struggle as a result of heightened competition and pharmacoeconomic constraints, suggests independent market analyst, Datamonitor. Over the last decade the targeted therapies and immunotherapies class has fuelled growth in the oncology market, making it very attractive…

28 Sep 2010, by Informa Insights


J&J in Talks to Buy Crucell | Expert Analyst Comment

[tweetmeme source= "informa_oz" only_single=false] Johnson & Johnson is in advanced negotiations to buy Dutch biotechnology company Crucell NV for €1.75 billion ($2.29 billion), the two companies said today. Giles Somers, senior healthcare analyst at Datamonitor comments: “So, one more big Pharma enters the vaccines space – following the example of Pfizer (through the acquisition of…

28 Sep 2010, by Informa Insights


Multi-blockbuster sales expected as Gilenya changes Multiple Sclerosis landscape

[tweetmeme source= "informa_oz" only_single=false] Melbourne, 23rd September 2010 - Gilenya is set to become the leading treatment in multiple sclerosis (MS) with multi-blockbuster sales, ending the decade long dominance of interferon betas and Copaxone (glatiramer acetate, Teva) says Trung Huynh, healthcare analyst at Datamonitor. “The FDA approved Novartis’s Gilenya (formally Gilenia; fingolimod) yesterday. It is…

28 Sep 2010, by Informa Insights

Education | Healthcare

new subgroups on Linkedin!

[tweetmeme source= "informa_oz" only_single=false] Exciting news everyone! We're slowly reorganising our groups and subgroups in Linkedin and will be updating the blog to keep YOU update on the latest subgroups created so that you can connect with the industry/sector that you want to! We've created 2 new subgroups under the Informa Healthcare Community parent group.…

22 Sep 2010, by Informa Insights


Informa Interview – Prof Peter Matthews on dual sector

[tweetmeme source= "informa_oz" only_single=false] We had the chance to speak to Professor Peter Matthews, Head of the Arts Academy at the University of Ballarat and Project Director of the Dual Sector Collaboration Project. The Inaugural Dual Sector Forum being held on 28th and 29th October in Melbourne has been developed by Informa in partnership with…

17 Sep 2010, by Informa Insights


Australian Obesity Summit Exclusive Interviews

[tweetmeme source= "informa_oz" only_single=false] We had the opportunity to speak to Professor Boyd Swinburn, Population Health, and Director of WHO Collaboration Centre for Obesity Prevention, Deakin University, about fighting the pressure for the over consumption of poor foods. [youtube=] **************** Watch Sharif Deen, Personal Trainer of Sharifit and Former Contestant of The Biggest Loser, as…

7 Sep 2010, by Informa Insights


Exclusive interviews from Health Congress 2010

[tweetmeme source= "informa_oz" only_single=false] We had the opportunity to interview Dr Clive Wright, Chief Dental Officer, NSW Health about the impact of dental disease on general health and wellbeing and if there is a need for a universal scheme for access to dental care. [youtube=] ***************** We had the opportunity to speak to David Crosbie,…

7 Sep 2010, by Informa Insights
Page  of 153

Get all the latest on Informa news and events

Informa Connect Australia is the nation's leading event organiser. Our events comprise of large scale exhibitions, industry conferences and highly specialised corporate training.

Find out more

Subscribe to Insights

Join Our Newsletter
Informa Insights

Stay up-to-date with all the latest
updates, upcoming events & more.
COVID-19 Informa Connect Update + Policy
Learn More